DV Trading LLC Makes New $998,000 Investment in OnKure Therapeutics, Inc. $OKUR

DV Trading LLC purchased a new stake in shares of OnKure Therapeutics, Inc. (NASDAQ:OKUR) in the first quarter, according to the company in its most recent filing with the SEC. The firm purchased 240,963 shares of the company’s stock, valued at approximately $998,000. DV Trading LLC owned about 0.60% of OnKure Therapeutics at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of OKUR. Vivo Capital LLC purchased a new stake in OnKure Therapeutics in the first quarter valued at approximately $7,981,000. ADAR1 Capital Management LLC lifted its position in OnKure Therapeutics by 140.1% during the first quarter. ADAR1 Capital Management LLC now owns 2,434,941 shares of the company’s stock valued at $10,081,000 after purchasing an additional 1,420,783 shares during the last quarter. Rosalind Advisors Inc. purchased a new position in OnKure Therapeutics in the 4th quarter worth approximately $2,118,000. Shay Capital LLC grew its stake in OnKure Therapeutics by 417.8% in the 2nd quarter. Shay Capital LLC now owns 782,046 shares of the company’s stock worth $1,869,000 after buying an additional 631,008 shares in the last quarter. Finally, Prosight Management LP grew its stake in OnKure Therapeutics by 204.9% in the 4th quarter. Prosight Management LP now owns 816,909 shares of the company’s stock worth $2,369,000 after buying an additional 548,950 shares in the last quarter. Hedge funds and other institutional investors own 90.98% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on OKUR. JonesTrading cut shares of OnKure Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 7th. Weiss Ratings cut OnKure Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday. HC Wainwright lowered their price target on OnKure Therapeutics to $21.00 and set a “buy” rating on the stock in a research report on Monday, July 20th. Finally, Wall Street Zen upgraded OnKure Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, June 6th. One equities research analyst has rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $21.00.

OnKure Therapeutics Price Performance

Shares of OKUR opened at $3.82 on Friday. OnKure Therapeutics, Inc. has a 1 year low of $1.91 and a 1 year high of $5.38. The stock has a 50 day simple moving average of $4.26 and a two-hundred day simple moving average of $3.80. The firm has a market cap of $154.33 million, a P/E ratio of -0.88 and a beta of 0.27.

OnKure Therapeutics (NASDAQ:OKUR) last posted its quarterly earnings results on Tuesday, May 5th. The company reported ($1.11) EPS for the quarter, missing the consensus estimate of ($0.74) by ($0.37). On average, equities analysts anticipate that OnKure Therapeutics, Inc. will post -2.57 earnings per share for the current year.

About OnKure Therapeutics

OnKure Therapeutics, Inc (NASDAQ: OKUR) is a clinical-stage biopharmaceutical company focused on the development of novel therapies for oncology and autoimmune diseases. Headquartered in Westlake Village, California, OnKure is advancing small molecule drug candidates designed to modulate key signaling pathways implicated in cancer cell growth and immune system function.

The company’s lead oncology asset, OKI-179, is an orally available histone deacetylase (HDAC) inhibitor being evaluated in Phase I and Phase II clinical studies for a range of solid tumors.